Company profile
BioRegenx, Inc.
OTC: BRGX · Healthcare · Medical - Diagnostics & Research
#811 of 1,418 Healthcare companies by revenue28th-percentile growth
EA Score
30DFH 35DQ 18GM 42SS 23
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, Piotroski F · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$1.8M
Rev growth YoY (TTM)
-23.4%
Net income (FY)
-$1.5M
Employees
6
as of 2026-08-23
Market cap
$5.8M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.9M$1.9M2025
Net income-$1.5M-$1.5M2025
Operating income-$1.2M-$1.2M2025
Total assets$411.0k$411.0k2025
Liabilities$4.9M$4.9M2025
Equity-$4.5M-$4.5M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Other Sales100%
By geography
Not disclosed.
The read
What is BioRegenx, Inc.’s revenue?
BioRegenx, Inc. booked $1.9M in FY2025 revenue, contracting 21% year over year — slower than 72% of Healthcare companies we track, at a -83.2% net margin.
Peers · Healthcare
Vycor Medical, Inc.56CPharmaCielo Ltd.40DWest Island Brands Inc.——Beleave Inc.——Bionik Laboratories Corp.——Nutranomics, Inc.——Neighbors
Hamilton →Key facts
CEOWilliam Resides
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersChattanooga, TN
ExchangeOTC: BRGX
Employees6
IPO date2024-05-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.